Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias

Psychopharmacology

Volumn 185, Issue 3, 2006, Pages 369-377

  Konitsiotis, Spiridon ^a   Tsironis, Christos ^a   Kiortsis, Dimitrios N ^a   Evangelou, Angelos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Amantadine; Jaw tremor; NMDA; NMDA receptor antagonist; Orofacial dyskinesia; Tardive dyskinesia; Tongue protrusions; Vacuous chewing movements

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; AMANTADINE; DEXTRORPHAN; HALOPERIDOL; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MEGADOSE; HUMAN; LONG TERM EXPOSURE; MALE; MOVEMENT (PHYSIOLOGY); NONHUMAN; OROFACIAL DYSKINESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; TARDIVE DYSKINESIA;

ALLOSTERIC REGULATION; AMANTADINE; ANIMALS; ANTIPSYCHOTIC AGENTS; DEXTRORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; MALE; PHENOLS; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 33645107344     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0348-9     Document Type: Article

References (39)

1. Andreassen OA, Aamo TO, Joorgensen HA (1996) Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br J Pharmacol 119:751-757
2. Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, Jorgensen HA (2003) Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 122:717-725
3. Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM (1997) A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 17:88-99
4. Blanchet PJ, Metman LV, Mouradian MM, Chase TN (1996) Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 11:580-581
5. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN (1999) Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-Methyl-4-phenyl- tetrahydropyridine monkeys. J Pharmacol Exp Ther 290:1034-1040
6. Buller AL, Larson HC, Schneider BE, Beaton JA, Morrisett RA, Monaghan DT (1994) The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. J Neurosci 14:5471-5484
7. Casey DE (2000) Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiat 61(Suppl 4):5-9
8. Casey DE (2004) Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65(Suppl 9):25-28
9. Chase TN, Oh JD, Konitsiotis S (2000) Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol 247(Suppl 2):II36-II42
10. Church J, Lodge D, Berry SC (1985) Differential effects of dextrorphan and levorphanol on the excitation of rat spinal neurons by amino acids. Eur J Pharmacol 111:185-190
11. Egan MF, Kurd Y, Ferguson J, Bachus SE, Hamid EH, Hyde TM (1996) Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology (Berl) 127:337-345
12. Fiorentini C, Missale C (2004) Oligomeric assembly of dopamine D1 and glutamate NMDA receptors: molecular mechanisms and functional implications. Biochem Soc Trans 32:1025-1028
13. Glazer WM (2000) Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 61(Suppl 4):15-20
14. Gomez-Mancilla B, Bedard PJ (1993) Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16:418-427
15. Gupta S, Mosnik D, Black DW, Berry S, Masand PS (1999) Tardive dyskinesia: review of treatments past, present, and future. Ann Clin Psychiatry 11:257-266
16. Hashimoto K, Mantione CR, Spada MR, Neumeyer JL, London ED (1994) Further characterization of [3H]ifenprodil binding in rat brain. Eur J Pharmacol 266:67-77
17. Hashimoto T, Ross DE, Gao XM, Medoff DR, Tamminga CA (1998) Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia. Psychopharmacology (Berl) 137:107-112
18. Kane J (1995) Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 1485-1495
19. Lee CS, Cenci MA, Schulzer M, Bjorklund A (2000) Embryonic ventral mesencephalic grafts improve levodopa - induced dyskinesia in a rat model of Parkinson's disease. Brain 123:1365-1379
20. Loschmann PA, De Groote C, Smith L, Wullner U, Fischer G, Kemp JA, Jenner P, Klockgether T (2004) Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol 187:86-93
21. Mealing GA, Lanthorn TH, Murray CL, Small DL, Morley P (1999) Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J Pharmacol Exp Ther 288:204-210
22. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN (1999) Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 56:1383-1386
23. Metman LV, Konitsiotis S, Chase TN (2000) Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord 15:3-8
24. Monaghan DT, Larsen H (1997) NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology. J Pharmacol Exp Ther 280:614-620
25. Montastruc JL, Rascol O, Senard JM, Rascol A (1992) A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J Neurol Neurosurg Psychiatry 55:630-631
26. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256:1217-1221
27. 3H] Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J Neurochem 70:2147-2155
28. 3 receptor antagonists. Eur J Pharmacol 420:113-117
29. Nakanishi S (1992) Molecular diversity of glutamate receptors and implications for brain function. Science 258:597-603
30. Papa SM, Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 39:574-578
31. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239-1258
32. Robertson RG, Farmery MA, Sambrook MA, Crossman AR (1989) Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res 476:317-322
33. Rogawski MA (1992) The NMDA receptor, NMDA antagonists and epilepsy therapy. A status report. Drugs 44:279-292
34. Rupniak NM, Boyce S, Steventon MJ, Iversen SD, Marsden CD (1992) Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys. Ann Neurol 32:103-105
35. Turrone P, Remington G, Nobrega JN (2002) The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci Biobehav Rev 26:361-380
36. Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natte R, Chase TN (1998a) A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 13:414-417
37. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998b) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50:1323-1326
38. Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN (1998c) Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51:203-206
39. Verhagen ML, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN (2002) Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 59:694-699